AI method lowers radiation dose, speeds scanning times
An artificial intelligence (AI) technique developed at Massachusetts General...Read more on AuntMinnie.comRelated Reading: AI advances MRI for prostate cancer patients Is artificial intelligence ethical in healthcare? Deep learning may produce sharp reductions in DBT dose AI can help distinguish lung nodules on CT scans Can AI help in the fight against gadolinium deposition?
Researchers examined whether a higher Gleason score impacts the efficacy of androgen deprivation therapy.
A recent study inJAMA Oncology compared survival for various multi-modality approaches for treating aggressive prostate cancer.
Back pain is a common complaint with many possible causes. In some cases, chronic, unexplained back pain can occur with advanced prostate cancer. Learn more here.
Conditions: Fatigue; Prostate Carcinoma Interventions: Behavioral: Exercise Intervention; Drug: Methylphenidate; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Other: Stretching Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
ConclusionCompared to DTI, DKI provides complementary and additional information about prostate cancer tissue, resulting more sensitive to PCa-derived modifications and more accurate in discriminating low- and high-risk PCa.
ConclusionmiR-21/146a/155 might be useful potential factors of radiosensitivity and acute genitourinary radiotoxicity in prostate cancer patients. miRNA might have great potential as predictors of various pathological conditions extracted from PBMCs.
Publication date: 10 December 2018Source: Cancer Cell, Volume 34, Issue 6Author(s): Clarissa Gerhauser, Francesco Favero, Thomas Risch, Ronald Simon, Lars Feuerbach, Yassen Assenov, Doreen Heckmann, Nikos Sidiropoulos, Sebastian M. Waszak, Daniel Hübschmann, Alfonso Urbanucci, Etsehiwot G. Girma, Vladimir Kuryshev, Leszek J. Klimczak, Natalie Saini, Adrian M. Stütz, Dieter Weichenhan, Lisa-Marie Böttcher, Reka Toth, Josephine D. HendriksenSummaryIdentifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We ...
Publication date: 10 December 2018Source: Cancer Cell, Volume 34, Issue 6Author(s): Joshua W. Russo, Steven P. BalkIn this issue of Cancer Cell, Gerhauser et al. analyze early-onset prostate cancers, showing roles for androgen receptor-driven rearrangements, an early APOBEC-driven mutational mechanism, and ESRP1 gene duplication. Through integration of whole-genome, transcriptome, and methylome data, they identify high-risk subgroups and develop an algorithm that may predict molecular evolution.
[Premium Times] On Saturday 8th December 2018, Janssen, one of the Pharmaceutical Companies of Johnson&Johnson, invited guests to 'More Time For Life!', a one day health and social networking event that aimed to encourage men to be more proactive in taking control of their health in general and prostate health in particular.
The use of androgen-deprivation therapy (ADT) in men with prostate cancer is associated with an increased risk of heart failure, researchers from Taiwan report.Reuters Health Information